| Date | Title | Description |
| 04.03.2025 | Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy | Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study)
Barcelona, Spain – 4 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapie... |
| 10.11.2022 | Minoryx y Neuraxpharm se alían para ofrecer una nueva terapia a los pacientes con enfermedades raras del SNC en Europa | 09/11/2022
Nota de prensa
MINORYX Y NEURAXPHARM SE ALÍAN PARA OFRECER UNA NUEVA TERAPIA A LOS PACIENTES CON ENFERMEDADES RARAS DEL SNC EN EUROPA
Minoryx Therapeutics, compañía biotecnológica en fase avanzada especializada en el desarroll... |
| 20.09.2022 | Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD | Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD) |
| 07.06.2022 | Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy | Minoryx Therapeutics, a Phase 3 stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, today announces it has closed a €51 million financing, including Series C equity financing and... |
| 31.05.2022 | Minoryx Therapeutics closes €51M Series C round co-led by ColumbusVP and CaixaCR. Also backed by CDTI, Fund+, Ysios and current investors | 31/05/2022
Press release
YSIOS CAPITAL JOINS ITS PORTFOLIO COMPANY. MINORYX THERAPEUTICS, €51 MILLION FINANCING.
Ysios Capital participates in the € 51M financing of Minoryx Therapeuticsto support Marketing Authorization Application and ... |
| 31.05.2022 | Minoryx Raises EUR 51M in Series C Funding | Minoryx Therapeutics, a Mataró, Barcelona, Spain-based Phase 3 stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, closed a EUR 51m financing, including Series C equity financing... |
| 31.05.2022 | Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy
Minoryx raises €51 million to support Marketing Aut... | Funds will support the marketing authorization review process for male patients with AMN and launch preparations in Europe, as well as activities required for US approval pathway |
| 31.05.2022 | Minoryx cierra una ronda Serie C de €51M coliderada por ColumbusVP y CaixaCR. Acuden también CDTI, Fund+, Ysios y otros inversores actuales | 31/05/2022
Nota de prensa
MINORYX CONSIGUE €51 MILLONES PARA FINANCIAR LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN Y LA PREPARACIÓN DEL LANZAMIENTO DE LERIGLITAZONA PARA X-ALD.
Los fondos apoyarán el proceso de solicitud de la autor... |
| 31.05.2022 | Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market | Minoryx has persuaded investors to overlook the failure of its phase 2/3 clinical trial, enabling it to reel in 51 million euros ($55 million) to support attempts to bring the rare disease drug to market in Europe and the U.S.
Roche helped ... |
| 03.11.2021 | Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021
Presentation highlights reduction in cerebral lesion progression and the risk... | Mataró, Barcelona, Spain, November 3, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces th... |
| 30.10.2020 | EIB provides Minoryx with up to €25M to support development of breakthrough therapies in orphan neurodegenerative diseases | 30/10/2020
Press release
EUROPEAN INVESTMENT BANK PROVIDES MINORYX WITH UP TO €25M TO SUPPORT DEVELOPMENT OF BREAKTROUGH THERAPIES IN ORPHAN NEURODEGENERATIVE DISEASES.
EIB support to develop breakthrough treatmentsto address orphan neuro... |
| 30.10.2020 | El BEI proporciona €25M a Minoryx para apoyar el desarrollo de terapias innovadoras en enfermedades raras neurodegenerativas | 30/10/2020
Nota de prensa
EL BANCO EUROPEO DE INVERSIONES PROPORCIONA €25M A MINORYX PARA APOYAR EL DESARROLLO DE TERAPIAS INNOVADORAS EN ENFERMEDADES RARAS NEURODEGENERATIVAS.
El BEI apoya al desarrollo de tratamientos innovadores para h... |
| 08.10.2020 | Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau | Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of innovative treatments for orphan Central ... |
| 08.10.2020 | Minoryx Therapeutics y Sperogenix Therapeutics firman un acuerdo de licencia exclusivo para desarrollar y comercializar leriglitazona en China continental, Hong Kong y Macao | Sperogenix Therapeutics, una plataforma dedicada al desarrollo y comercialización de terapias para enfermedades raras en China, y Minoryx Therapeutics, una empresa especializada en el desarrollo de tratamientos innovadores para enfermedades... |
| 24.09.2020 | Minoryx, participada por firmas de VC, cierra un acuerdo de licencia con la farmacéutica china Sperogenix para el fármaco leriglitazona | 24/09/2020
Nota de prensa
MINORYX, PARTICIPADA POR FIRMAS DE VENTURE CAPITAL, CIERRA UN ACUERDO DE LICENCIA CON LA FARMACÉUTICA CHINA SPEROGENIX PARA EL FÁRMACO LERIGLITAZONA.
Minoryx, participada por firmas de venture capital, recibirá ... |
| 15.10.2019 | Reata to seek approval for Friedreich’s ataxia drug on positive Phase II results | The company said that patients treated with the drug at 150mg per day showed a statistically significant, placebo-corrected 2.40-point improvement on the modified Friedreich’s Ataxia Rating Scale, or mFARS after 48 weeks of treatment. The c... |
| 16.07.2019 | Life Sciences and Gaming Startups Bloom in Barcelona | Barcelona has some of the most fascinating architecture in the world, with landmarks like La Sagrada Familia, Casa Batlló, and Parc Güell. This inspiring setting is also one of the largest entrepreneurial hubs in Southern Europe with local ... |
| 15.03.2019 | AstraZeneca vet Jennifer Butler takes charge of Innate Pharma's US biz; C4 raids NIBR | → France’s Innate Pharma has wooed AstraZeneca vet Jennifer Butler to lead the US operations it has set up after acquiring Lumoxiti from the British drugmaker in a rich add-on collaboration deal. Butler’s official ti... |
| 26.09.2018 | Roche-backed Minoryx raises €21M to expand CNS R&D
W h i t e p a p e r
Weighing the Costs: | Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of organizations including Roche Venture Fund.
Sponsored by A... |
| 26.09.2018 | Minoryx cierra una ronda Serie B de €21,3M liderada por Fund+, acuden SRIW, SFPI-FPIM, Sambrinvest e inversores anteriores | 26/09/2018
Nota de prensa
MINORYX CIERRA UNA RONDA SERIE B DE €21,3 MILLONES LIDERADA POR FUND+, ACUDEN SRIW, SFPI-FPIM, SAMBRINVEST E INVERSORES ANTERIORES.
Minoryx Therapeutics, compañía especializada en el desarrollo de nuevos medicam... |
| 26.09.2018 | Term Sheet — Wednesday, September 26 | THE UNRAVELING
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
The departures make sense given that Social Capital is no longer a venture firm but rather a “technology holding company.... |
| 26.09.2018 | Roche-backed Minoryx raises €21M to expand CNS R&D | Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of organizations including Roche Venture Fund.
Spain’s Minory... |
| 26.09.2018 | Minoryx Therapeutics raises €21.3M in Series B funding round | Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the completion of a Series B funding round of €21.3M. The proceeds will enable the company to expand the list of indications f... |
| 26.09.2018 | Minoryx Therapeutics Raises €21.3M in Series B Funding | Minoryx Therapeutics, a Mataró, Barcelona, Spain-based company specializing in the development of new drugs for orphan diseases, completed a €21.3M Series B funding round.
The round was led by Fund+, joined by SFPI, S.R.I.W. and Sambrinvest... |
| 20.07.2017 | Novartis, Sanofi-backed NeuroVia closes $14M series A for X-ALD work | Sanofi Genzyme and Novartis’ venture arms have backed NeuroVia, an upstart that wants to help treat the rare CNS disorder X-linked adrenoleukodystrophy.
The $14 million series A, which was also backed by BioMed Ventures and Enso Ventures, w... |
| 25.10.2016 | Spanish biotech sector gets a boost with $140 million VC fund | “With our recent investments we have been able to attract specialized international funds and corporate venture funds to Spain, which represents an inflection point for the country´s biotech sector,” said Joel Jean-Mairet, partner at Ysios ... |
| 27.01.2016 | Minoryx Therapeutics appoints Dr. Khalid Islam as chairman of the board of directors | Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces the appointment of Dr. Khalid Islam as chairman of the board of directors. Dr. Islam has 27 years experience in ... |
| 14.10.2015 | Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M) | Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces it has completed a Series A funding round of €19.4M ($21.7M). Ysios Capital, a Spanish investment fund, led the ... |
| 14.10.2015 | Roche backs €19M round to move Minoryx's CNS drug into the clinic | Roche Venture Fund has contributed to a big day for another Spanish biotech. Minoryx Therapeutics is the latest of the country's biotechs to cash in, raising €19.4 million ($21.7 million) in a round led by Ysios Capital and supported by Roc... |
| 14.10.2015 | Minoryx Therapeutics cierra una ronda de €19,4M liderada por Ysios. Acuden CaixaCR, Kurma, Roche VF, Idinvest, Chiesi y Health Equity | 14/10/2015
MINORYX THERAPEUTICS CIERRA UNA RONDA DE €19,4 MILLONES LIDERADA POR YSIOS CAPITAL. ACUDEN CAIXA CAPITAL RISC, KURMA PARTNERS, ROCHE VENTURE FUND, IDINVEST, CHIESI VENTURES Y HEALTH EQUITY.
Minoryx Therapeutics, una compañía es... |
| 14.10.2015 | Minoryx Therapeutics Completes €19.4M Series A Funding | Minoryx Therapeutics, a Mataró, Barcelona, Spain-based drug development company specialized in the discovery of new drugs for orphan diseases, completed a €19.4M ($22.1M) Series A funding round.
The round was led by Ysios Capital, with part... |
| 09.10.2015 | Daily funding roundup - October 14, 2015 | Area 1 Security raised $15M
eMMs, Inc. secured over $2 million in company's Series-A round of funding from private South African individual investor to build the cyber data protection fortress, FortKnoxx. Patent pending, FortKnoxx Fortress ... |
| 31.03.2015 | Healthequity invierte €750.000 en la biotecnológica catalana Minoryx | 31/03/2015
HEALTHEQUITY INVIERTE €750.000 EN LA BIOTECNOLÓGICA CATALANA MINORYX.
Healthequity, el fondo de capital riesgo (venture capital) promovido por el Colegio Oficial de Médicos de Barcelona y el grupo financiero Riva y García, ha i... |
| 23.01.2015 | Caixa Capital Risc lidera una ronda de €1,6 millones en Minoryx | 23/01/2015
CAIXA CAPITAL RISC LIDERA UNA RONDA DE €1,6 MILLONES EN MINORYX.
La Caixa ha liderado una ronda de financiación de €1,6 millones en la empresa Minoryx. La inversión se ha realizado a través del fondo Caixa Innvierte BioMed II, ... |
| 23.01.2015 | ”la Caixa” leads a 1.6 million Euro round in Minoryx | ”la Caixa” has led a 1.6 million Euro round of funding in the Minoryx company. The investment has been made through the Caixa Innvierte BioMed II fund, an investment vehicle managed by Caixa Capital Risc, the venture capital arm of ”la Caix... |
| 04.04.2013 | Minoryx Therapeutics Raises €1.5M in First Funding | Minoryx Therapeutics, a Mataró, Barcelona, Spain-based company focused on finding novel treatments for life threatening rare diseases, raised €1.5m in its first funding.
Backers included Caixa Capital Risc and Inveready, via Inveready Biote... |
| 02.04.2013 | La Caixa e Inveready invierten en Minoryx | 02/04/2013
Nota de Prensa
LA CAIXA E INVEREADY INVIERTEN EN MINORYX.
Las entidades de capital riesgo (venture capital) Caixa Capital Risc y Grupo Inveready, a través de sus vehículos Caixa Capital Micro e Inveready Biotech II, respectiva... |
| - | Spanish biotech sector gets a boost with $140 million VC fund | Ysios Capital Directors Josep Ll. Sanfeliu (top left), Joël Jean-Mairet, Karen Wagner, Julia Salaverria (left to right), and Cristina Garmendia (right bottom).
Institutional and private investors have given the Spanish biotech sector a powe... |
| - | Reata to seek approval for Friedreich’s ataxia drug on positive Phase II results | Shares of a small biotech company skyrocketed Tuesday following the release of positive data from its registration-directed Phase II study of a fatal genetic disorder that causes muscle weakness.
Irving, Texas-based Reata Pharmaceuticals ro... |
